G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company that develops and delivers next-generation therapies to improve the lives of individuals impacted by cancer. The company’s first commercial product is COSELA® (trilaciclib), and it is evaluating therapies in combination with cytotoxic therapies and/or immunotherapy for conditions with high unmet needs, such as triple-negative breast cancer and extensive stage small cell lung cancer. G1 Therapeutics aims to provide innovative therapeutic solutions for cancer patients.
On May 1, 2024, G1 Therapeutics will be hosting a webcast and conference call to provide a financial and corporate update for the first quarter of 2024. The event will begin at 8:30 a.m. ET, and interested individuals can register by following the provided link on the company’s website. It is recommended to join the event 10 minutes prior to the start time. A live and archived webcast will be available on the Events & Presentations page of the company’s website for those who are unable to attend the live event.
For any further information or inquiries, individuals can contact G1 Therapeutics’ Communications Officer and Vice President of Investor Relations and Corporate Communications, Will Roberts, at (919) 907-1944 or via email at wroberts@g1therapeutics.com. Trademarks owned by G1 Therapeutics, Inc. include G1 Therapeutics®, COSELA®, and their respective logos.